NPI-001 for preserving vision in usher syndrome
Part of Brain & nervous system, Ear, nose & throat, Eyes & vision, Genetic & congenital clinical trials.
This study tests a 24-month treatment with NPI-001, an oral medication, to see if it can slow the loss of light-sensing cells in the retina for people with retinitis pigmentosa tied to Usher syndrome. It aims to preserve remaining vision and delay further damage.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have retinitis pigmentosa (RP) associated with Usher syndrome.
- You have some healthy retina tissue left in both eyes—specifically, an EZ width of at least 500 microns that includes the fovea (the sharp vision area).
- You see enough points on a special eye test (MAIA microperimetry) to show that your vision is stable enough.
- Your other medications have been at a steady dose for at least a month.
- If you could become pregnant, you must be willing to use birth control during the 24-month trial.
- You haven't had eye surgery in the last 2 months, and you don't have other eye diseases like glaucoma or diabetic retinopathy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This 24-month study tests an experimental medication, NPI-001, to see if it can slow or prevent further vision loss in people with Usher syndrome. Usher syndrome affects hearing and vision, and this trial focuses on protecting the light-sensing cells in the retina.
This trial tests a new form of the drug pitavastatin, which is usually used for cholesterol, but here it's given as tiny particles injected into the eye. The goal is to see if it's safe and might help people with retinitis pigmentosa, a condition that causes vision loss.
This trial tests a gentle laser treatment (SML) for people with retinitis pigmentosa (RP), an inherited eye disease that slowly causes vision loss. The goal is to see if the laser can help slow or improve vision problems like night blindness and tunnel vision.
This study tests a new gene therapy called UGX202 for people with advanced retinitis pigmentosa, an eye disease that causes vision loss. The goal is to see if it is safe and if it can help improve vision.
This trial tests an investigational gene therapy injection (UGX202) for people with advanced retinitis pigmentosa. The goal is to see if the injection is safe and can help preserve or improve vision in people who still have some memory of seeing.
This study follows people with Usher syndrome type 1B over time to learn how vision loss progresses. It also tests new ways to measure functional vision, which may help design future treatments.
Hear when a new Usher Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.